Mai Kato

Efficacy and safety of ustekinumab in Japanese patients with moderate‐to‐severe plaque‐type psoriasis: Long‐term results from a phase 2/3 clinical trial

Atsuyuki Igarashi, Takeshi Kato, Mai Kato et al. · The Journal of Dermatology · 2011 · 204 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13

Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

Daisuke Yabe, Jiro Nakamura, Hideaki Kaneto et al. · The Lancet Diabetes & Endocrinology · 2020 · 203 citations

Medicine, Pharmacology, Pharmacotherapy +15

The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-co

O. Nemoto, M. Furue, Hidemi Nakagawa et al. · British Journal of Dermatology · 2015 · 189 citations · Full text

Medicine, Dermatology, Pharmacology +17

Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial

Norio Hayashi, Namiki Izumi, Hiromitsu Kumada et al. · Journal of Hepatology · 2014 · 140 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Phase 2a, randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study of a H₄R‐antagonist (<scp>JNJ</scp>‐39758979) in<scp>J</scp>apanese adults with moderate atopic dermatitis

Yoko Murata, Michael Song, Hisayuki Kikuchi et al. · The Journal of Dermatology · 2014 · 129 citations · Full text

Medicine, Dermatology, Pharmacotherapy +16